SCHEMBL9907382

SCHEMBL9907382

O=C(O)c1ccc2ccnc(-c3cccc(Cl)c3Cl)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.47
TTR P02766 3/20 0.40
KMO O15229 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
PLA2G2D Q9UNK4 1/20 0.39
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
MEN1 O00255 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SLC22A12 Q96S37 1/20 0.38
AURKA O14965 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9925229 0.86 HTR5A (0.40) PLAU
SCHEMBL9907376 0.85 TP53 (0.44) KDM4CRAB9AKMT2AHTTSMN1; SMN2
SCHEMBL9907374 0.85 PLAU (0.50) PLAUTTRKMOPLA2G2DAURKA
SCHEMBL9907913 0.83 HTR5A (0.55) PLAU
SCHEMBL7918853 0.81 PLA2G2D (0.48) TTRMRGPRX4PLA2G2DMEN1RAB9A
SCHEMBL9907383 0.81 KDM4C (0.49) PLAUTTRKMOMRGPRX4KDM4C
SCHEMBL16502616 0.81 DOT1L (0.45) PLAUTTRPLA2G2DMEN1RAB9A
SCHEMBL9907728 0.81 HTR5A (0.46) PLAUTTRMRGPRX4SLC22A12MAP4K4
SCHEMBL16502684 0.80 PLAU (0.50) PLAUMRGPRX4PLA2G2DKDM4CMEN1
SCHEMBL9907373 0.80 HTR5A (0.50) PLAUTTRKMOPLA2G2DEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E PLAU 3322/4885TTR 3634/4885KMO 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.